SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab Injection
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Early-stage or Locally Advanced HER2-positive Breast Cancer
Conditions
Early-stage or Locally Advanced HER2-positive Breast Cancer
Trial Timeline
Oct 23, 2025 → Dec 1, 2028
NCT ID
NCT07196774About SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab Injection
SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab Injection is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Early-stage or Locally Advanced HER2-positive Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07196774. Target conditions include Early-stage or Locally Advanced HER2-positive Breast Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07196774 | Phase 3 | Recruiting |
Competing Products
9 competing products in Early-stage or Locally Advanced HER2-positive Breast Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Anastrozole + Trastuzumab Deruxtecan | Daiichi Sankyo | Phase 2 | 52 |
| ICG | Johnson & Johnson | Pre-clinical | 23 |
| Tamoxifen alone + Tamoxifen + Aminoglutethimide | AstraZeneca | Phase 3 | 77 |
| Cyclophosphamide + Methotrexate + Fluorouracil implant + Goserelin + Tamoxifen | AstraZeneca | Phase 3 | 77 |
| ABP 234 + Pembrolizumab | Amgen | Phase 3 | 76 |
| Rotigotine | UCB | Phase 3 | 74 |
| UCB0599 + Placebo | UCB | Phase 2 | 49 |
| Rasagiline + Pramipexole | Lundbeck | Approved | 82 |
| Neratinib + Loperamide + Colesevelam | Puma Biotechnology | Phase 2 | 44 |